Core Insights - The studies RETHINK-ALZ and REFOCUS-ALZ did not meet their pre-specified co-primary, secondary, or exploratory biomarker endpoints, but exploratory post-hoc analyses provided informative insights regarding the treatment effects of simufilam in specific patient subgroups [1][2][5] Study Overview - RETHINK-ALZ (NCT04994483) randomized 804 participants, while REFOCUS-ALZ (NCT05026177) included 1,125 patients, both focusing on mild to moderate Alzheimer's disease [3][9] - The trials were multi-center, double-blinded, placebo-controlled studies designed to evaluate the safety and efficacy of simufilam compared to placebo [9] Safety and Efficacy Findings - Simufilam demonstrated a favorable safety profile in the studies, with detailed safety observations reported [1][4] - In the predefined mild subgroup (MMSE score 21-27), simufilam (100 mg) was associated with slower cognitive decline compared to placebo at various weeks, with nominal significance at p = 0.01, 0.01, 0.02, 0.02, and 0.02 for Weeks 4, 28, 40, 52, and 64 respectively [5][6] Exploratory Analyses - Exploratory findings indicated potential treatment differences in the mild subgroup, with a prespecified pooled analysis showing nominal significance at p < 0.01 for Weeks 4 and 28 [5][6] - A post hoc analysis using a plasma p-tau181 cutoff of ≥ 67 showed significant differences in cognitive decline at Weeks 4, 28, and 40 (p = 0.03, 0.001, 0.006 respectively) [6] Future Directions - The company has discontinued the development of simufilam for Alzheimer's disease but aims to leverage the safety observations for ongoing development in TSC-related epilepsy [3][4][8] - Cassava Sciences plans to initiate a proof-of-concept study for simufilam in TSC-related epilepsy, collaborating with leading investigators [4][12]

Core Insights - Cassava Sciences, Inc. reported a net loss of $44.2 million for Q2 2025, a significant decline from a net income of $6.2 million in the same period of 2024 [2][13] - The company is advancing its investigational treatment simufilam for Tuberous Sclerosis Complex (TSC)-related epilepsy, with a proof-of-concept study planned for H1 2026 [5][9] - Cassava has appointed experienced neuroscience professionals to guide the clinical development of simufilam, enhancing its research capabilities [6][8] Financial Performance - Net cash used in operations for the first half of 2025 was $16.3 million, with expectations of $47 to $51 million for the second half, including a $31.25 million estimated loss contingency related to securities litigation [2][13] - Cash and cash equivalents stood at $112.4 million as of June 30, 2025, down from $128.6 million at the end of 2024 [13][22] - Research and development expenses decreased by 66% to $5.1 million in Q2 2025, primarily due to the phase-out of the Alzheimer's disease program [13][20] Business Developments - The company initiated a new program focused on TSC-related epilepsy, supported by positive preclinical studies showing a 60% reduction in seizure frequency in animal models [3][5] - Cassava has established collaborations with Yale University and the TSC Alliance to further its research on simufilam [9][12] - The appointment of Dr. Joseph Hulihan as Chief Medical Officer and other neuroscience leaders is expected to strengthen the clinical development strategy for simufilam [6][8] Market Context - TSC affects approximately 50,000 people in the US, with 80% to 90% of patients experiencing seizures, highlighting a significant unmet medical need for effective treatments [11][12] - Current therapies for TSC-related epilepsy are not fully effective and are associated with serious adverse events, indicating a potential market opportunity for simufilam [11][12]